​

C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CCCC Stock Forecast

C4 Therapeutics (CCCC) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $7.67, with a high of $10.00 and a low of $6.00. This represents a 178.91% increase from the last price of $2.75.

$2 $3 $4 $5 $6 $7 $8 $9 $10 $11 High: $10 Avg: $7.67 Low: $6 Last Closed Price: $2.75

CCCC Stock Rating

C4 Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (71.43%), 3 Hold (21.43%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 3 10 Strong Sell Sell Hold Buy Strong Buy

CCCC Price Target Upside V Benchmarks

TypeNameUpside
StockC4 Therapeutics178.91%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts126
Avg Price Target$7.00$6.00$7.67
Last Closing Price$2.75$2.75$2.75
Upside/Downside154.55%118.18%178.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2617---8
Feb, 2617---8
Jan, 2617---8
Dec, 2516---7
Nov, 2516---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 26, 2026Etzer DaroutBarclays$7.00$2.81149.11%154.55%
Dec 17, 2025Barclays$5.00$2.26121.24%81.82%
Sep 23, 2025Derek ArchilaWells Fargo$10.00$2.80257.14%263.64%
Sep 22, 2025Etzer DaroutBarclays$10.00$3.16216.46%263.64%
Sep 16, 2025Barclays$8.00$3.41134.60%190.91%
Sep 15, 2025Sudan LoganathanStephens$6.00$3.5768.07%118.18%
Dec 19, 2024Derek ArchilaWells Fargo$12.00$4.31178.42%336.36%
Sep 19, 2024Etzer DaroutBMO Capital$20.00$6.87191.12%627.27%
Jan 03, 2023Wells Fargo$9.00$6.3142.63%227.27%
Apr 28, 2022Credit Suisse$10.00$8.8512.99%263.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026BarclaysOverweightOverweighthold
Feb 26, 2026Cowen & Co.BuyBuyhold
Feb 23, 2026Brookline CapitalBuyBuyhold
Dec 02, 2025Cowen & Co.Buyinitialise
Sep 23, 2025Wells FargoOverweightOverweighthold
Sep 22, 2025BarclaysOverweightOverweighthold
Sep 16, 2025BarclaysOverweightinitialise
Sep 15, 2025StephensOverweightupgrade
Sep 03, 2025GuggenheimBuyinitialise
Dec 19, 2024Wells FargoEqual-WeightOverweightupgrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.82$-2.62$-2.67$-1.52$-1.27----
Avg Forecast$-2.05$-2.59$-2.60$-1.49$-1.41$-1.22$-1.20$-0.94$1.41
High Forecast$-2.05$-2.59$-2.33$-1.41$-1.35$-0.89$-0.62$-0.83$1.55
Low Forecast$-2.05$-2.59$-2.86$-1.58$-1.45$-1.55$-1.65$-1.03$1.24
Surprise %-11.22%1.16%2.69%2.01%-9.93%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$45.78M$31.10M$20.76M$35.58M-----
Avg Forecast$33.08M$39.80M$21.45M$35.79M$30.39M$21.62M$21.62M$118.30M$1.23B
High Forecast$33.08M$39.80M$28.59M$40.79M$32.72M$23.28M$21.62M$127.38M$1.32B
Low Forecast$33.08M$39.80M$17.13M$30.29M$27.66M$19.68M$21.62M$107.69M$1.12B
Surprise %38.40%-21.86%-3.25%-0.58%-----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-83.89M$-128.18M$-132.49M$-105.32M$-104.99M----
Avg Forecast$-100.64M$-117.73M$-132.49M$-74.23M$-97.23M$-84.61M$-78.75M$-64.93M$97.53M
High Forecast$-80.51M$-94.18M$-105.99M$-70.10M$-93.98M$-61.73M$-43.19M$-57.36M$107.26M
Low Forecast$-120.76M$-141.28M$-158.99M$-78.37M$-100.48M$-107.50M$-114.32M$-71.41M$86.16M
Surprise %-16.64%8.87%-41.87%7.99%----

CCCC Forecast FAQ

Is C4 Therapeutics stock a buy?

C4 Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that C4 Therapeutics is a favorable investment for most analysts.

What is C4 Therapeutics's price target?

C4 Therapeutics's price target, set by 14 Wall Street analysts, averages $7.67 over the next 12 months. The price target range spans from $6 at the low end to $10 at the high end, suggesting a potential 178.91% change from the previous closing price of $2.75.

How does C4 Therapeutics stock forecast compare to its benchmarks?

C4 Therapeutics's stock forecast shows a 178.91% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for C4 Therapeutics over the past three months?

  • March 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is C4 Therapeutics’s EPS forecast?

C4 Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.22, marking a -3.94% decrease from the reported $-1.27 in 2025. Estimates for the following years are $-1.2 in 2027, $-0.94 in 2028, and $1.41 in 2029.

What is C4 Therapeutics’s revenue forecast?

C4 Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $21.62M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $21.62M, followed by $118.3M for 2028, and $1.23B for 2029.

What is C4 Therapeutics’s net income forecast?

C4 Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-84.614M, representing a -19.41% decrease from the reported $-105M in 2025. Projections indicate $-78.754M in 2027, $-64.93M in 2028, and $97.53M in 2029.